Hasil Pencarian - Jingdong Chao

  • Menampilkan 1 - 11 hasil dari 11
Perbaiki Hasil
  1. 1
    Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease

    Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease oleh Yifei Liu, Joakim Söderberg, Jingdong Chao

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system.

    Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. oleh Raymond K Cross, Michael Chiorean, Francis Vekeman, Yongling Xiao, Eric Wu, Jingdong Chao, Anthony W Wang

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis

    Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis oleh David G Binion, Edouard Louis, Bas Oldenburg, Parvez Mulani, Arielle G Bensimon, Mei Yang, Jingdong Chao

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis.

    Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. oleh April W Armstrong, Ahong Huang, Li Wang, Raymond Miao, Miraj Y Patel, Abhijit Gadkari, Usha G Mallya, Jingdong Chao

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family

    Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family oleh Amy S. Paller, Servando E. Marron, Diane Whalley, Lauren Nelson, Shanshan Qin, Jingdong Chao, Ashish Bansal, Chien‐Chia Chuang, Zhixiao Wang

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

    Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s Disea... oleh Remo Panaccione, Edward V Loftus, David Binion, Kevin McHugh, Shamsul Alam, Naijun Chen, Benoît Guérette, Parvez Mulani, Jingdong Chao

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years

    Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years oleh Yi Zhang, Jennifer L. Clegg, Shannon Keith, Shehan McFadden, Tara Symonds, Rajesh Kumar, Asif H. Khan, Siddhesh Kamat, Jingdong Chao

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

    Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use oleh Mette Deleuran, Danielle Marcoux, Marjolein S. Bruin-Weller, Alan D. Irvine, Eulalia Baselga, Kangmo Ahn, Ana Paula Castro, Ashish Bansal, Jingdong Chao, Gaëlle Bégo-Le-Bagousse, Ana B. Rossi

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

    Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis oleh Jonathan I. Silverberg, Eric L. Simpson, Mark Boguniewicz, Marjolein S. De Bruin-Weller, Peter Foley, Yoko Kataoka, Gaëlle Bégo-Le-Bagousse, Zhen Chen, Brad Shumel, Jingdong Chao, Ana B. Rossi

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

    Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study oleh Alexa B. Kimball, Dimittri Delevry, Min Yang, Chien-Chia Chuang, Zhixiao Wang, Gaëlle Bégo-Le-Bagousse, Bruno Martins, Eric Wu, Brad Shumel, Jessie Wang, Debra Sierka, Jingdong Chao, Bruce Strober

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Efficacy of dupilumab in moderate and severe atopic dermatitis

    Efficacy of dupilumab in moderate and severe atopic dermatitis oleh Stephan Weidinger, Eric L. Simpson, Jonathan I. Silverberg, Jochen Schmitt, Yael A. Leshem, Norito Katoh, Zhen Chen, Haixin Zhang, Brad Shumel, Ashish Bansal, Jingdong Chao, Yufang Lu, Ana B. Rossi, Alvina Abramova

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: